Literature DB >> 26707377

Brucella abortus Omp19 recombinant protein subcutaneously co-delivered with an antigen enhances antigen-specific T helper 1 memory responses and induces protection against parasite challenge.

Lorena M Coria1, Andrés E Ibañez1, Karina A Pasquevich1, Paula L González Cobiello2, Fernanda M Frank2, Guillermo H Giambartolomei3, Juliana Cassataro4.   

Abstract

The discovery of effective adjuvants for many vaccines especially those with limited commercial appeal, such as vaccines to poverty-related diseases, is required. In this work, we demonstrated that subcutaneous co-administration of mice with the outer membrane protein U-Omp19 from Brucella spp. plus OVA as antigen (Ag) increases Ag-specific T cell proliferation and T helper (Th) 1 immune responses in vitro and in vivo. U-Omp19 treated dendritic cells promote IFN-γ production by specific CD4(+) T cells and increases T cell proliferation. U-Omp19 co-administration induces the production of Ag specific effector memory T cell populations (CD4(+) CD44(high) CD62L(low) T cells). Finally, subcutaneous co-administration of U-Omp19 with Trypanosoma cruzi Ags confers protection against virulent parasite challenge, reducing parasitemia and weight loss while increasing mice survival. These results indicate that the bacterial protein U-Omp19 when delivered subcutaneously could be a suitable component of vaccine formulations against infectious diseases requiring Th1 immune responses.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adjuvant; Brucella; Outer membrane protein; T helper 1; Vaccine

Mesh:

Substances:

Year:  2015        PMID: 26707377     DOI: 10.1016/j.vaccine.2015.12.012

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  U-Omp19 from Brucella abortus Is a Useful Adjuvant for Vaccine Formulations against Salmonella Infection in Mice.

Authors:  Gabriela S Risso; Marianela V Carabajal; Laura A Bruno; Andrés E Ibañez; Lorena M Coria; Karina A Pasquevich; Seung-Joo Lee; Stephen J McSorley; Gabriel Briones; Juliana Cassataro
Journal:  Front Immunol       Date:  2017-02-17       Impact factor: 7.561

2.  Salmonella Typhi Porins OmpC and OmpF Are Potent Adjuvants for T-Dependent and T-Independent Antigens.

Authors:  Marisol Pérez-Toledo; Nuriban Valero-Pacheco; Rodolfo Pastelin-Palacios; Cristina Gil-Cruz; Christian Perez-Shibayama; Mario A Moreno-Eutimio; Ingeborg Becker; Sonia Mayra Pérez-Tapia; Lourdes Arriaga-Pizano; Adam F Cunningham; Armando Isibasi; Laura C Bonifaz; Constantino López-Macías
Journal:  Front Immunol       Date:  2017-03-09       Impact factor: 7.561

Review 3.  Meta-Analysis of the Changes of Peripheral Blood T Cell Subsets in Patients with Brucellosis.

Authors:  Rongjiong Zheng; Songsong Xie; Shaniya Niyazi; Xiaobo Lu; Lihua Sun; Yan Zhou; Yuexin Zhang; Kai Wang
Journal:  J Immunol Res       Date:  2018-05-17       Impact factor: 4.818

4.  A Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Mice.

Authors:  Lorena M Coria; Lucas M Saposnik; Celeste Pueblas Castro; Eliana F Castro; Laura A Bruno; William B Stone; Paula S Pérez; Maria Laura Darriba; Lucia B Chemes; Julieta Alcain; Ignacio Mazzitelli; Augusto Varese; Melina Salvatori; Albert J Auguste; Diego E Álvarez; Karina A Pasquevich; Juliana Cassataro
Journal:  Front Immunol       Date:  2022-02-28       Impact factor: 7.561

5.  A disordered region retains the full protease inhibitor activity and the capacity to induce CD8+ T cells in vivo of the oral vaccine adjuvant U-Omp19.

Authors:  M Laura Darriba; Celeste Pueblas Castro; Lorena M Coria; Laura Bruno; M Laura Cerutti; Lisandro H Otero; Lucía B Chemes; Rodolfo M Rasia; Sebastián Klinke; Juliana Cassataro; Karina A Pasquevich
Journal:  Comput Struct Biotechnol J       Date:  2022-09-06       Impact factor: 6.155

6.  Stability Studies of the Vaccine Adjuvant U-Omp19.

Authors:  M Laura Darriba; María L Cerutti; Laura Bruno; Juliana Cassataro; Karina A Pasquevich
Journal:  J Pharm Sci       Date:  2020-10-12       Impact factor: 3.534

7.  U-Omp19 from Brucella abortus increases dmLT immunogenicity and improves protection against Escherichia coli heat-labile toxin (LT) oral challenge.

Authors:  Lorena M Coria; Franco L Martinez; Laura A Bruno; Karina A Pasquevich; Juliana Cassataro
Journal:  Vaccine       Date:  2020-06-11       Impact factor: 3.641

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.